Short-Acting B2 Agonists Market Report 2026

Short-Acting B2 Agonists Market Overview

• Short-Acting B2 Agonists market size has reached to $4.4 billion in 2025 • Expected to grow to $5.39 billion in 2030 at a compound annual growth rate (CAGR) of 4.2% • Growth Driver: Rising COPD Prevalence Fueling The Growth Of The Market Due To Increasing Demand For Rapid Symptom Relief • Market Trend: Advancements In Inhaler Technology For Efficient Acute Symptom Management • North America was the largest region in 2025.

What Is Covered Under Short-Acting B2 Agonists Market?

Short-acting beta-2 agonists are a class of medications commonly used to provide quick relief from symptoms of asthma and other respiratory conditions. These drugs work by stimulating beta-2 adrenergic receptors in the smooth muscle lining of the airways, leading to rapid bronchodilation or relaxation of the muscles around the airways. The main short-acting b2 agonists type include albuterol, levalbuterol, metaproterenol, and others. Albuterol refers to a widely used short-acting B2 agonist that provides rapid relief from bronchospasm by relaxing airway muscles. It is used for asthama, chronic obstructive pulmonary disease (copd), and exercise-induced bronchospasm and can be administered through inhalation, oral, and injection routes. It is used by various end users such as hospitals, clinics, and home healthcare settings.

What Is The Short-Acting B2 Agonists Market Growth Forecast?

The short-acting b2 agonists market size is expected to see steady growth in the next few years. It will grow to $5.39 billion in 2030 at a compound annual growth rate (CAGR) of 4.2%. The growth in the forecast period can be attributed to air pollution increase, urban respiratory disease burden, growth in home inhaler use, pediatric asthma cases, outpatient respiratory care expansion. Major trends in the forecast period include continued use as first-line rescue medication, rising asthma and copd prevalence, preference for inhalation-based delivery, growth of homecare respiratory treatment, expansion of generic saba products.

What Is The Driver Of The Short-Acting B2 Agonists Market?

The increasing prevalence of chronic obstructive pulmonary disease (COPD) is expected to propel the growth of the short-acting B2 agonists market going forward. Chronic obstructive pulmonary disease (COPD) is a long-term lung disease that causes breathing difficulties and reduced airflow, mainly due to prolonged exposure to harmful gases or cigarette smoke. The rise in chronic obstructive pulmonary disease (COPD) is due to increasing exposure to air pollution, as long-term inhalation of pollutants like particulate matter and toxic gases can harm lung tissue and accelerate the disease's development. Short-acting β2-agonists (SABAs) are used in COPD to quickly relieve symptoms like shortness of breath by relaxing airway muscles. They act as rescue medications during flare-ups but are not meant for long-term control. For instance, in December 2023, according to a research study published by JAMA Network Open, a medical journal by the American Medical Association, the global burden of chronic obstructive pulmonary disease (COPD) projected that the cases worldwide could reach nearly 600 million by 2050, marking a 23% increase in prevalence. Therefore, the increasing prevalence of chronic obstructive pulmonary disease will boost the growth of the short-acting B2 agonists industry.

Key Players In The Global Short-Acting B2 Agonists Market

Major companies operating in the short-acting b2 agonists market are AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Apotex Inc., Perrigo Company plc, Aurobindo Pharma Ltd., Chiesi Farmaceutici S.p.A., Cipla Limited, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals Inc., Lupin Limited, Orion Corporation, Beximco Pharmaceuticals Ltd., Micro Labs Limited, Neuland Laboratories Limited, Vectura Group plc, Nephron Pharmaceuticals Corporation, AdvaCare Pharma USA LLC, Midas Care Pharmaceuticals Pvt Ltd.

Global Short-Acting B2 Agonists Market Trends and Insights

Major companies in the short-acting B2 agonists market are focusing on developing technologically advanced products, such as pressurized metered-dose inhalers (pMDI), to help manage acute symptoms efficiently. Pressurized metered-dose inhalers (pMDIs) are handheld devices that deliver a specific dose of medication to the lungs in aerosol form using a propellant-driven spray commonly used for treating respiratory conditions like asthma and COPD. For instance, in January 2023, AstraZeneca, a UK-based pharmaceutical and biotechnology company, announced the US Food and Drug Administration (FDA) approval for Airsupra (albuterol/budesonide). Airsupra is a first-in-class pressurized metered-dose inhaler (pMDI) that combines two active ingredients in a fixed-dose formulation. It contains albuterol, a short-acting beta2-agonist (SABA), for rapid bronchodilation, and budesonide, an inhaled corticosteroid (ICS), to reduce inflammation. This unique combination is approved in the US for the as-needed treatment and prevention of bronchoconstriction in adults with asthma. Additionally, it helps reduce the risk of exacerbations, providing a comprehensive approach to asthma management.

What Are Latest Mergers And Acquisitions In The Short-Acting B2 Agonists Market?

In April 2024, Teva Pharmaceutical Industries Ltd., an Israel-based manufacturer of short-acting B2 agonists, collaborated with Launch Therapeutics Inc. to help expedite Teva's ICS clinical research program-SABA (TEV-'248). With this collaboration, Teva Pharmaceutical Industries aims to accelerate the development and commercialization of its innovative dual-action asthma rescue inhaler to provide a more effective treatment option for adult and pediatric asthma patients. Launch Therapeutics Inc. is a US-based clinical development company.

What Defines the Short-Acting B2 Agonists Market?

The short-acting beta-2 agonists market consists of sales of nebulizer solutions, combination inhalers, respiratory monitoring devices, spacers and holding chambers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Short-Acting B2 Agonists Market Report 2026?

The short-acting b2 agonists market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the short-acting b2 agonists industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.